Avirmax Biopharma to Showcase Innovative Ocular Gene Therapies
Avirmax Biopharma Inc. (ABI) will present its exciting advancements in gene therapy for ocular diseases at the upcoming American Academy of Ophthalmology (AAO) 2024 annual meeting. This prestigious event takes place in a prime location to gather experts and stakeholders dedicated to eye health. Avirmax will host its exhibit at booth #5357, where they plan to demonstrate their latest achievements and ongoing progress within their ocular programs.
Pioneering Gene Therapy Innovations
Driven by a strong commitment to deliver effective treatments, Avirmax Biopharma concentrates on the promising potential of adeno-associated virus (AAV) based therapies designed specifically for retinal conditions. Their innovative approach involves developing proprietary AAV2.N54 capsids tailored to enhance gene delivery directly to the macula, crucial for achieving optimal therapeutic outcomes. By ensuring safe administration through intravitreal injections, Avirmax’s therapies aim for prolonged efficacy, potentially diminishing the necessity for frequent treatment sessions.
Cost-Effective Manufacturing Solutions
Avirmax operates an advanced in-house cGMP manufacturing facility that leverages proprietary VSaf™ virus-free Sf9 cell lines. This innovative manufacturing technique significantly reduces the cost of gene therapy vector production to just 5-10% of conventional methods. Such efficiency not only enhances product safety but also ensures that next-generation genetic medicines become accessible to a vastly increased number of patients suffering from retinal diseases globally.
Unique Pipeline Addressing Unmet Ophthalmic Needs
According to Dr. Wendy Murahashi, Chief Medical Officer, Avirmax Biopharma’s diverse pipeline aims at addressing numerous critical needs within ophthalmology that remain unmet. This includes ABI-110, their flagship candidate targeting wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV), which is currently in Phase I/IIa clinical trials.
Promising Clinical Developments
Preliminary results have indicated that ABI-110 showcases markedly improved tropism to the macular retina when evaluated against traditional AAV serotypes, demonstrated in several animal models, including mice, rabbits, pigs, and non-human primates. Furthermore, the ABI-201 program focuses on advancing therapies for geographic atrophy (GA), dry AMD, and proliferative diabetic retinopathy (PDR). Strategy for ABI-902 includes targeting a range of glaucoma types, currently under nonclinical development.
About Avirmax Biopharma
Avirmax Biopharma, headquartered in the San Francisco Bay Area, stands at the forefront of developing cutting-edge gene therapies for various ocular conditions, including wet AMD, PCV, dry AMD, glaucoma, and diabetic retinopathy. Their mission revolves around harnessing proprietary AAV vector technologies to deliver safe and effective solutions that enhance patient results while preserving vision.
Contact Information
For further inquiries, please contact June Song, Associate Director for Operations, at +1-510-641-0201. Avirmax Biopharma remains committed to innovation in ocular treatments, ensuring effective communication and information dissemination about their pioneering work.
Frequently Asked Questions
What is Avirmax Biopharma's main focus?
Avirmax Biopharma primarily focuses on developing next-generation gene therapies intended to address various ocular diseases, particularly those affecting the retina.
Where will Avirmax exhibit its innovations?
Avirmax will exhibit its advancements at the AAO 2024 annual meeting, specifically at booth #5357.
What is the significance of ABI-110?
ABI-110 is Avirmax's leading therapy targeting wet AMD and PCV, noted for its enhanced efficacy in preclinical studies compared to traditional treatments.
How does Avirmax ensure affordability in their therapies?
The company utilizes a unique manufacturing process that significantly lowers production costs, making their therapies more accessible to a larger patient population.
What innovative technologies is Avirmax using?
Avirmax employs proprietary AAV vector technologies and maintains cutting-edge facilities to ensure the safety and effectiveness of their gene therapies.
